{"id":"https://openalex.org/W2356820007","doi":"https://doi.org/10.1002/cpdd.272","title":"Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects","display_name":"Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects","publication_year":2016,"publication_date":"2016-05-10","ids":{"openalex":"https://openalex.org/W2356820007","doi":"https://doi.org/10.1002/cpdd.272","mag":"2356820007","pmid":"https://pubmed.ncbi.nlm.nih.gov/27162089","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5132079"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.272","doi":"https://doi.org/10.1002/cpdd.272","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.272","pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.272","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.272","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058472962","display_name":"Yu Lou","orcid":"https://orcid.org/0009-0007-1343-6064","observed_orcids":["https://orcid.org/0009-0007-1343-6064"]},"institutions":[{"id":"https://openalex.org/I4210124468","display_name":"PAREXEL International (United States)","ror":"https://ror.org/02vkbzw76","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124468"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu Lou","raw_affiliation_strings":["Parexel International, Research Triangle Park, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parexel International, Research Triangle Park, Durham, NC, USA","institution_ids":["https://openalex.org/I4210124468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024692584","display_name":"Ann M. Buchanan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ann M. Buchanan","raw_affiliation_strings":["ViiV Healthcare, Research Triangle Park, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Research Triangle Park, Durham, NC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100751113","display_name":"Shuguang Chen","orcid":"https://orcid.org/0000-0001-8441-657X","observed_orcids":["https://orcid.org/0000-0001-8441-657X"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shuguang Chen","raw_affiliation_strings":["GlaxoSmithKline, Upper Providence, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Upper Providence, PA, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009272615","display_name":"Susan L. Ford","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124468","display_name":"PAREXEL International (United States)","ror":"https://ror.org/02vkbzw76","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124468"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan L. Ford","raw_affiliation_strings":["Parexel International, Research Triangle Park, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parexel International, Research Triangle Park, Durham, NC, USA","institution_ids":["https://openalex.org/I4210124468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042067535","display_name":"Elizabeth P. Gould","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119210","display_name":"Chimerix (United States)","ror":"https://ror.org/02jsvy381","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119210"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Gould","raw_affiliation_strings":["Chimerix, Research Triangle Park, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chimerix, Research Triangle Park, Durham, NC, USA","institution_ids":["https://openalex.org/I4210119210"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008716404","display_name":"David M. Margolis","orcid":"https://orcid.org/0000-0001-5714-0002","observed_orcids":["https://orcid.org/0000-0001-5714-0002"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Margolis","raw_affiliation_strings":["ViiV Healthcare, Research Triangle Park, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Research Triangle Park, Durham, NC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044001938","display_name":"William R. Spreen","orcid":"https://orcid.org/0000-0002-8180-1517","observed_orcids":["https://orcid.org/0000-0002-8180-1517"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William R. Spreen","raw_affiliation_strings":["ViiV Healthcare, Research Triangle Park, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Research Triangle Park, Durham, NC, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103010175","display_name":"Parul Patel","orcid":"https://orcid.org/0000-0001-7002-4348","observed_orcids":["https://orcid.org/0000-0001-7002-4348"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Parul Patel","raw_affiliation_strings":["ViiV Healthcare, Research Triangle Park, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ViiV Healthcare, Research Triangle Park, Durham, NC, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5103010175"],"corresponding_institution_ids":[],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":{"value":3800,"currency":"USD","value_usd":3800},"fwci":1.6511,"has_fulltext":true,"cited_by_count":13,"citation_normalized_percentile":{"value":0.85834947,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"5","issue":"6","first_page":"509","last_page":"516"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10217","display_name":"Cardiac electrophysiology and arrhythmias","score":0.725600004196167,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10217","display_name":"Cardiac electrophysiology and arrhythmias","score":0.725600004196167,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.21389999985694885,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","score":0.010300000198185444,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cabotegravir","display_name":"cabotegravir","score":1.0},{"id":"https://openalex.org/keywords/cardiac-repolarization","display_name":"cardiac repolarization","score":0.9259999990463257},{"id":"https://openalex.org/keywords/qt-interval","display_name":"QT interval","score":0.9350000023841858},{"id":"https://openalex.org/keywords/qtcf","display_name":"QTcF","score":0.8640000224113464},{"id":"https://openalex.org/keywords/moxifloxacin","display_name":"moxifloxacin","score":0.8619999885559082},{"id":"https://openalex.org/keywords/hiv-integrase-inhibitors","display_name":"HIV integrase inhibitors","score":0.6600000262260437},{"id":"https://openalex.org/keywords/supratherapeutic-dose","display_name":"supratherapeutic dose","score":0.7149999737739563},{"id":"https://openalex.org/keywords/plasma-concentration","display_name":"plasma concentration","score":0.4620000123977661},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5370000004768372},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.43700000643730164}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8788456320762634},{"id":"https://openalex.org/C118441451","wikidata":"https://www.wikidata.org/wiki/Q12074763","display_name":"QT interval","level":2,"score":0.6907660961151123},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6196326613426208},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.48140931129455566},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.4761081635951996},{"id":"https://openalex.org/C2778836808","wikidata":"https://www.wikidata.org/wiki/Q424940","display_name":"Moxifloxacin","level":3,"score":0.4278098940849304},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.40413352847099304},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3078981339931488},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.07971540093421936},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077266","descriptor_name":"Moxifloxacin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004562","descriptor_name":"Electrocardiography","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006321","descriptor_name":"Heart","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006329","descriptor_name":"Heart Conduction System","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006339","descriptor_name":"Heart Rate","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008133","descriptor_name":"Long QT Syndrome","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D024841","descriptor_name":"Fluoroquinolones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D054659","descriptor_name":"Diketopiperazines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1002/cpdd.272","doi":"https://doi.org/10.1002/cpdd.272","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.272","pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.272","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4087102","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5132079","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5132079","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5132079","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol Drug Dev","raw_type":"Text"},{"id":"pmid:27162089","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27162089","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1002/cpdd.272","doi":"https://doi.org/10.1002/cpdd.272","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.272","pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.272","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320312382","display_name":"ViiV Healthcare","ror":"https://ror.org/01cc9yk21"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2356820007.pdf","grobid_xml":"https://content.openalex.org/works/W2356820007.grobid-xml"},"referenced_works_count":14,"referenced_works":["https://openalex.org/W1612898398","https://openalex.org/W1674196795","https://openalex.org/W1975763725","https://openalex.org/W1984220118","https://openalex.org/W2032800042","https://openalex.org/W2038481443","https://openalex.org/W2051107872","https://openalex.org/W2052746866","https://openalex.org/W2069279736","https://openalex.org/W2081607626","https://openalex.org/W2085167526","https://openalex.org/W2085405111","https://openalex.org/W2113818541","https://openalex.org/W2135417699"],"related_works":["https://openalex.org/W2051107872","https://openalex.org/W1984866560","https://openalex.org/W3034054116","https://openalex.org/W1520730363","https://openalex.org/W3038779726","https://openalex.org/W1480294397","https://openalex.org/W2980853513","https://openalex.org/W1992338967","https://openalex.org/W1577872972","https://openalex.org/W4400429820"],"abstract_inverted_index":{"A":[0],"randomized,":[1],"partial-blind,":[2],"repeat-dose,":[3],"3-period":[4],"crossover":[5],"study":[6],"(NCT02027454)":[7],"assessed":[8],"the":[9,62,84,116],"effect":[10,224],"of":[11,41,61,135,138,147],"cabotegravir":[12,27,123,139,163,174,182,217],"on":[13,87,119,225],"QT":[14,90],"interval":[15,91],"in":[16,155,205],"healthy":[17],"subjects.":[18],"To":[19],"achieve":[20],"a":[21,39,56,67,184,219],"supratherapeutic":[22,220],"dose,":[23],"each":[24],"subject":[25,180],"received":[26],"150":[28,136],"mg":[29,31,137],"(30":[30],"\u00d7":[32],"5":[33],"tablets)":[34],"every":[35,141],"12":[36,50,142],"hours":[37,82,102,110,114],"for":[38,74,99,152,160],"total":[40],"3":[42,133,196],"doses":[43,134],"over":[44,52],"2":[45,53,109],"days,":[46,54],"matching":[47],"placebo":[48],"(every":[49],"hours)":[51],"or":[55,194,197,201,210],"single":[57],"open-label":[58],"400-mg":[59],"dose":[60,86,118,221],"positive":[63],"control":[64],"moxifloxacin,":[65],"with":[66],"21-day":[68],"washout":[69],"between":[70,162,173],"treatments.":[71],"Blood":[72],"samples":[73],"pharmacokinetic":[75],"analyses":[76],"were":[77,93,166,191],"collected":[78],"up":[79],"to":[80,112],"24":[81,101,113],"after":[83,115],"third":[85,117],"day":[88,120],"2.":[89,121],"data":[92,214],"obtained":[94],"by":[95],"continuous":[96],"Holter":[97],"monitoring":[98],"approximately":[100,126],"at":[103,218],"baseline":[104,159],"(day":[105],"-1)":[106],"and":[107,164,177],"from":[108,158],"before":[111],"Plasma":[122],"exposure":[124],"was":[125,170],"3-fold":[127],"above":[128],"clinically":[129,202],"relevant":[130],"doses.":[131],"After":[132],"administered":[140],"hours,":[143],"all":[144],"upper":[145],"limits":[146],"2-sided":[148],"90%":[149],"confidence":[150],"intervals":[151],"\u0394\u0394QTcF":[153],"(difference":[154],"time-matched":[156],"change":[157],"QTcF":[161,185],"placebo)":[165],"<10":[167],"milliseconds.":[168,189],"There":[169,190],"no":[171,192,223],"relationship":[172],"plasma":[175],"concentrations":[176],"\u0394\u0394QTcF.":[178],"No":[179],"receiving":[181],"had":[183,222],"value":[186],">":[187],"450":[188],"serious":[193],"grade":[195],"4":[198],"adverse":[199],"events":[200],"significant":[203],"changes":[204],"laboratory":[206],"values,":[207],"vital":[208],"signs,":[209],"electrocardiogram":[211],"results.":[212],"These":[213],"demonstrate":[215],"that":[216],"cardiac":[226],"repolarization.":[227]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}